8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4 Linagliptin Entèmedyè Pite ≥99.0% (HPLC) Faktori

Deskripsyon kout:

Non: 8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine

CAS: 666816-98-4

Pite: ≥99.0% (HPLC)

Aparans: poud blan ak blan

Entèmedyè pou Linagliptin (CAS: 668270-12-0) pou tretman adilt ki gen dyabèt tip 2.

Segondè Kalite, Pwodiksyon Komèsyal

E-Mail: alvin@ruifuchem.com

Voye imèl ba nou

Pwodwi detay

Pwodwi ki gen rapò

Tags pwodwi

Deskripsyon:

Manifakti bay Linagliptin ak entèmedyè ki gen rapò:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4
2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidin CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Pwopriyete chimik:

Non Chimik	8-Bromo-7-(2-butin-1-yl) -3-methylxanthine
Sinonim	8-Bromo-7-(2-butin-1-yl) -3,7-dihydro-3-methyl-1H-purine-2,6-dyon;Linagliptin entèmedyè C
Nimewo CAS	666816-98-4
Nimewo CAT	RF-PI497
Estati Stock	Nan Stock, Pwodiksyon Echèl Jiska Tòn
Fòmil molekilè	C10H9BrN4O2
Pwa molekilè	297.11
Pwen k ap fonn	285℃
Mak	Ruifu Chimik

Espesifikasyon:

Atik	Espesifikasyon
Aparans	Poud blan pou blan
Dlo (KF)	≤0.50%
Rezid sou ignisyon	≤0.50%
Pite / Metòd analiz	≥99.0% (HPLC)
Max Single enpurte	≤0.50%
Solvang rezidyèl
Etanòl	≤5000ppm
DMF	≤3000ppm
Tès Creole	Enterprise Standard
Itilizasyon	Entèmedyè pou Linagliptin (CAS: 668270-12-0)

Pake & Depo:

Pake: Boutèy, sache papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an.

Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite.

Avantaj:

FAQ:

Aplikasyon:

8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine (CAS: 666816-98-4) se yon entèmedyè pou Linagliptin (CAS: 668270-12-0).Linagliptin se yon inibitè oral, trè selektif nan dipeptidyl peptidase-4 epi li se premye ajan nan klas li yo ki elimine sitou atravè yon wout ki pa ren.Linagliptin endike pou itilize yon fwa chak jou pou tretman adilt ki gen dyabèt tip 2.Linagliptin te apwouve pa US FDA nan mwa me 2011 pou tretman dyabèt tip 2 ansanm ak rejim alimantè ak fè egzèsis.